After going ‘crazy’ over the science, Merck signs up a new partner in the hunt for an HIV cure

Max Gelman

Senior Editor

Less than a year after inking a $100 million licensing deal with German giant Bayer, Dewpoint Therapeutics has scored another big-time contract, this time with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After going ‘crazy’ over the science, Merck signs up a new partner in the hunt for an HIV cure

Max Gelman

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Af­ter go­ing ‘crazy’ over the sci­ence, Mer­ck signs up a new part­ner in the hunt for an HIV cure

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

After going ‘crazy’ over the science, Merck signs up a new partner in the hunt for an HIV cure